Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 6/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1470461 | 0.81 | FFAR1 (0.62) | HTR6PPARDFFAR1MTNR1AMTNR1B | |
| SCHEMBL7847075 | 0.81 | FFAR1 (0.62) | HTR6PPARDFFAR1MTNR1AMTNR1B | |
| SCHEMBL7845908 | 0.81 | FFAR1 (0.62) | HTR6PPARDFFAR1MTNR1AMTNR1B | |
| SCHEMBL11732903 | 0.78 | MTNR1A (0.49) | HTR6PPARDFFAR1MTNR1AMTNR1B | |
| SCHEMBL1567606 | 0.78 | MTNR1A (0.51) | HTR6PPARDFFAR1MTNR1AMTNR1B | |
| SCHEMBL7296740 | 0.76 | MTNR1A (0.50) | HTR6PPARDFFAR1MTNR1AMTNR1B | |
| SCHEMBL4714587 | 0.76 | HTR6 (0.51) | HTR6PPARDFFAR1MTNR1AMTNR1B | |
| SCHEMBL14356155 | 0.76 | MTNR1B (0.50) | HTR6PPARDFFAR1MTNR1AMTNR1B | |
| SCHEMBL6184833 | 0.76 | HTR6 (0.51) | HTR6PPARDFFAR1MTNR1AMTNR1B | |
| SCHEMBL6272803 | 0.76 | MTNR1B (0.50) | HTR6PPARDFFAR1MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115658-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase | AGOURON PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20040023958-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2003095441-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023958-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | POLRMT, RNGTT, RNASE1 | HTR6 4782/4885PPARD 2666/4885FFAR1 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.